These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
629 related articles for article (PubMed ID: 10583007)
1. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke Therapy Academic Industry Roundtable (STAIR) Stroke; 1999 Dec; 30(12):2752-8. PubMed ID: 10583007 [TBL] [Abstract][Full Text] [Related]
2. Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials. Philip M; Benatar M; Fisher M; Savitz SI Stroke; 2009 Feb; 40(2):577-81. PubMed ID: 19074479 [TBL] [Abstract][Full Text] [Related]
3. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Savitz SI; Fisher M Ann Neurol; 2007 May; 61(5):396-402. PubMed ID: 17420989 [TBL] [Abstract][Full Text] [Related]
4. Emerging neuroprotective drugs for the treatment of acute ischaemic stroke. Schmidt A; Minnerup J; Kleinschnitz C Expert Opin Emerg Drugs; 2013 Jun; 18(2):109-20. PubMed ID: 23600899 [TBL] [Abstract][Full Text] [Related]
5. Drug therapies for stroke and traumatic brain injury often display U-shaped dose responses: occurrence, mechanisms, and clinical implications. Calabrese EJ Crit Rev Toxicol; 2008; 38(6):557-77. PubMed ID: 18615310 [TBL] [Abstract][Full Text] [Related]
6. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Savitz SI Exp Neurol; 2007 May; 205(1):20-5. PubMed ID: 17408618 [TBL] [Abstract][Full Text] [Related]
7. Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Green AR Clin Exp Pharmacol Physiol; 2002 Nov; 29(11):1030-4. PubMed ID: 12366397 [TBL] [Abstract][Full Text] [Related]
8. Animal models of stroke: do they have value for discovering neuroprotective agents? Richard Green A; Odergren T; Ashwood T Trends Pharmacol Sci; 2003 Aug; 24(8):402-8. PubMed ID: 12915049 [TBL] [Abstract][Full Text] [Related]
9. Why do neuroprotective drugs work in animals but not humans? DeGraba TJ; Pettigrew LC Neurol Clin; 2000 May; 18(2):475-93. PubMed ID: 10757837 [TBL] [Abstract][Full Text] [Related]
15. Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies. Broussalis E; Trinka E; Killer M; Harrer A; McCoy M; Kraus J Drug Discov Today; 2012 Jul; 17(13-14):671-84. PubMed ID: 22405898 [TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibition with roscovitine: neuroprotection in acute ischemic stroke. Timsit S; Menn B Clin Pharmacol Ther; 2012 Feb; 91(2):327-32. PubMed ID: 22218073 [TBL] [Abstract][Full Text] [Related]
17. The failure of neuronal protective agents versus the success of thrombolysis in the treatment of ischemic stroke. The predictive value of animal models. Jonas S; Aiyagari V; Vieira D; Figueroa M Ann N Y Acad Sci; 2001 Jun; 939():257-67. PubMed ID: 11462778 [TBL] [Abstract][Full Text] [Related]
18. Neuroprotective therapies: Preclinical reproducibility is only part of the problem. Tymianski M Sci Transl Med; 2015 Aug; 7(299):299fs32. PubMed ID: 26246165 [TBL] [Abstract][Full Text] [Related]
19. New approaches to neuroprotective drug development. Fisher M Stroke; 2011 Jan; 42(1 Suppl):S24-7. PubMed ID: 21164111 [TBL] [Abstract][Full Text] [Related]
20. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Gladstone DJ; Black SE; Hakim AM; Stroke; 2002 Aug; 33(8):2123-36. PubMed ID: 12154275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]